drugset / Trial / NCT05111912
Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity
Phase 2
Completed
206 enrolled
Sciwind Biosciences APAC CO Pty. Ltd.
Hangzhou Sciwind Biosciences Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
XW003 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.
Timeline
- Start
- 2021-11-30
- Primary completion
- 2022-11-16
- Completion
- 2022-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ecnoglutide | Protein / enzyme biologic | 1.2 mg | — |
| Subject | Ecnoglutide | Protein / enzyme biologic | 1.8 mg | — |
| Subject | Ecnoglutide | Protein / enzyme biologic | 2.4 mg | — |
| Comparator | Liraglutide | Peptide | 3 mg | — |